Alliance for Pandemic Preparedness

October 12, 2020

Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19

Category:

Topic:

Keywords (Tags):

  • Among 86 pregnant and postpartum women with severe COVID-19 who received compassionate use of remdesivir, recovery rates were high (93% for pregnant women and 89% for postpartum women) and there were few serious adverse events (16% of all participants). At the beginning of treatment with remdesivir, 40% of pregnant women required invasive ventilation, compared to 95% of postpartum women. At 28-day follow-up, 93% of pregnant women who had been on mechanical ventilation had been extubated, 93% had recovered, and 90% were discharged. Among postpartum women, 89% had been extubated, 89% had recovered, and 84% were discharged. [EDITORIAL NOTE: The lack of a comparable group that did not receive remdesivir means that it is not possible to evaluate the efficacy of treatment in this study population.]

Burwick et al. (Oct 8, 2020). Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa1466